1 Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE) block allergen-induced contraction of passively sensitized human airways in vitro by a dual mechanism involving a direct relaxant eect on smooth muscle and inhibition of histamine and cysteinyl leukotriene (LT) release from airways. We investigated the eects of non-selective PDE inhibitors and selective inhibitors of PDE3 and PDE4 in order to determine the involvement of PDE isoenzymes in the suppression of allergic bronchoconstriction. 2 Macroscopically normal airways from 76 patients were sensitized with IgE-rich sera (4250 u ml
Introduction
Extrinsic bronchial asthma is characterized by increased airway responsiveness to non-speci®c and speci®c stimuli, such as histamine, leukotrienes and allergen. Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as the methylxanthine, theophylline, have been used in the treatment of bronchial asthma for several decades (Weinberger & Hendeles, 1996) and are included in current guidelines (National Institutes of Health, 1995; . Besides inducing mild bronchodilation (Pauwels et al., 1985; Ward et al., 1993) , PDE inhibitors have been shown to reduce airway in¯ammation (Banner & Page, 1996; Karlsson, 1996) and to be eective against early and late phase allergic asthmatic responses. The mechanisms by which methylxanthines exert these eects appear to involve adenosine receptor antagonism (Karlsson, 1987; Crimi et al., 1989; Coward et al., 1998) and ± through elevation of intracellular adenosine 3':5'-cyclic monophosphate (cyclic AMP) concentrations (Bergstrand, 1980; Hill et al., 1999 ) ± a direct relaxant eect on smooth muscle, as well as inhibition of mediator release from in¯ammatory cells (Louis et al., 1992) .
It is well known, however, that treatment with theophylline can cause considerable side-eects, such as cardiac dysrhythmias and nausea, which are believed to result mainly from non-selective PDE inhibition and to a lesser extent from adenosine receptor antagonism. Since the immunopharmacology of theophylline has been broadly investigated in recent years, the development of novel selective PDE inhibitors with signi®cant anti-in¯ammatory and bronchospasmolytic properties but an improved side-eect pro®le has attracted particular interest.
To date, 10 PDE isoenzyme gene families have been identi®ed (Beavo, 1995; Conti et al., 1995; Fisher et al., 1998; tissues. Among them, PDE1 through PDE5 are found in human airways. Functional studies with selective PDE inhibitors have suggested a major role for PDE3 and PDE4 isoenzymes in the regulation of airway tone (Rabe et al., 1993) . Moreover, PDE4 appears to be the predominant isoenzyme in various in¯ammatory cells, such as monocytes and monocyte-derived macrophages (Gantner et al., 1997) , B lymphocytes (Cooper et al., 1985) and eosinophils (Dent et al., 1994) .
Under in vivo as well as in vitro conditions, allergeninduced bronchoconstriction of human airways is believed to result from the formation and release of in¯ammatory mediators, mainly cysteinyl leukotrienes (BjoÈ rck et al., 1991; BjoÈ rck & DahleÂ n, 1993; Roquet et al., 1997) . Owing to the fact that PDE3 and PDE4 are involved in the regulation of airway tone as well as mediator release from in¯ammatory cells, the aim of our study was to evaluate their speci®c role in airway responses to allergen. Therefore, we investigated the eects of PDE inhibitors selective for PDE3, PDE4 or PDE3/4 on allergen-and leukotriene C 4 (LTC 4 )-induced contractions in passively sensitized human airways in vitro. For comparison, an adenosine receptor antagonist and nonselective PDE inhibitors were included in the study.
Methods

Tissue preparations
Macroscopically normal airways were obtained from 76 patients undergoing surgery for lung cancer. None were chronically treated with theophylline, b-adrenoceptor agonists, corticosteroids or anticholinergic drugs. Preoperative lung function parameters were generally normal. Serum IgE levels on the day of surgery were determined for all patients. Immediately after resection, peripheral airways (1 ± 4 mm internal diameter) were dissected free of alveolar tissue and cut into rings (2 ± 4 mm length).
Passive sensitization
The sensitizing serum was prepared from whole blood of individuals who demonstrated high total IgE (4250 u ml 71 ) and speci®c IgE antibodies (¯uorescent immunosorbent test [FAST] class 53) against allergen (Dermatophagoides farinae). Sera were not pooled but were frozen individually in 200 ± 250-ml aliquots until required. Tissues were rotated overnight at room temperature in tubes containing modi®ed Krebs buer (composition in mM: NaCl 118.4, KCl 4.7, MgSO 4 0.6, CaCl 2 1.3, KH 2 PO 4 1.2, NaHCO 3 25.0, glucose 11.1), in the absence or presence of sensitizing serum (10% vol vol
71
). The next morning rings were transferred to 10-ml organ baths containing oxygenated (95% O 2 , 5% CO 2 ) modi®ed Krebs buer (pH 7.4, 378C) and bronchial responses were recorded using isometric force displacement transducers (model FT-03; Stag Instruments Limited, Oxon, U.K.) coupled to a Multitrace 8 chart recorder (Lectromed, Welwyn Garden City, Herts, U.K.).
Tension measurements
Tissues were equilibrated for at least 60 min at a resting tension of about 400 mg before a single concentration (1 mM) of the b-adrenoceptor agonist isoprenaline was applied to determine the amount of inherent tone. After full recovery of the tissues, histamine concentration-eect curves (10 nM ± 300 mM) were performed. Contractile responses as measured in mg weight were recorded.
After washing and re-equilibration to stable tension, sensitized tissues were pre-treated for 30 min with one of the drugs listed in Table 1 and changes in bronchial tone were measured. Thereafter, drug eects on allergen concentration-eect curves (0.03 ± 30 u ml 71 ) were assessed and compared to responses in untreated, passively sensitized control tissues from the same patient. Similarly, eects of the highest concentration of each drug on LTC 4 concentration-eect curves (3 pM ± 0.3 mM) were evaluated. All concentration-eect curves were constructed in a cumulative manner, using incremental concentrations spaced at half log 10 intervals. To investigate the eect of selective PDE inhibition on pre-contracted bronchi, in some experiments motapizone (1 mM) and RP73401 (300 nM) were added after completion of the allergen concentration-eect curves. At the end of the experiments, tissues were exposed to a single concentration of carbachol (0.1 mM) to ensure that the absence of contractile responses was not the result of deterioration of a bronchial ring. Finally, tissue wet weights were determined at the end of the experiments.
Measurements and analysis of results
All responses were recorded as absolute changes in isometric tension. The traces were evaluated manually. The potency of histamine and LTC 4 was calculated from concentration-eect curves by non-linear curve-®tting using the Prism 1 program (GraphPad TM Software, San Diego, CA, U.S.A.) for each individual tissue and expressed as pD 2 . Histamine, leukotriene and allergen concentration-eect curves were compared for the dierent conditions (passively sensitized versus non-sensitized, drug pre-treatment versus vehicle controls) using repeated-measures analysis of variance (ANOVA), with the dierent conditions as between-group factor and histamine, leukotriene and allergen concentrations as within-group factor. In testing for statistically signi®cant dierences between curves, the between-group eect (level) and its interaction with the within-group eect (slope) were taken into account. To compare the eects of an individual drug on leukotriene-versus allergen-induced contractions, responses after drug treatment were expressed as per cent inhibition with respect to the respective vehicle control and compared at those allergen and leukotriene concentrations that induced approximately 75% of the maximal response to histamine. These data were compared using the unpaired, two-tailed t-test. For the purpose of data comparison between passively sensitized and non-sensitized tissues (resting tension, inherent tone, wet weights, maximal contraction and pD 2 ) the paired t-test was used. All values quoted are mean+s.e.mean. The level of statistical signi®-cance was de®ned as P40.05.
Isoprenaline, histamine and carbachol were dissolved in distilled water. LTC 4 was dissolved in Hanks balanced salts solution containing 1% (wt vol 71 ) bovine serum albumin. Allergen was diluted in normal saline. For the respective solvents of the drugs see Table 1 .
Results
Baseline characteristics of the bronchial rings
The mean (+s.e.mean) wet weight of the passively sensitized bronchial rings was 11.2+0.56 mg, mean resting tension was 425+11 mg weight and mean inherent tone (i.e. the magnitude of relaxation after a single dose of isoprenaline) was 241+14 mg weight.
Effect of passive sensitization on responses to histamine, LTC 4 and allergen
Histamine and LTC 4 caused concentration-dependent contractions in both sensitized and non-sensitized bronchial ring preparations. In accordance with previously published data (Schmidt et al., 1999) , passive sensitization led to a signi®cant increase in responsiveness to histamine and LTC 4 as compared to non-sensitized paired control tissues from the same patient (ANOVA P50.001 for both stimuli; Table 2 ). D. farinae caused concentration-dependent contractions in sensitized tissues but not in non-sensitized control tissues, as indicated by the dierence in maximal contraction ( Figure 1 , Table 2 ). The respective solvents of the drugs (Table 1) did not signi®cantly alter responses to LTC 4 or allergen in sensitized bronchial rings.
Relationship among histamine, LTC 4 and allergen contraction-effect curves
Maximal contractions of non-sensitized and sensitized bronchial rings in response to LTC 4 were of the same magnitude as maximal contractions to histamine ( Figure 1 , Table 2 ). However, on average, LTC 4 was 9500 fold more (Schudt et al., 1991a) 10 mM HCl 0.1 ± 1 mM RP73401 PDE4 267 0.001 (Ashton et al., 1994) 1% DMSO 3 ± 300 nM Rolipram PDE4 768 1.5 (Ashton et al., 1994) 0.001% EtOH 1 ± 30 mM AWD 12 ± 281 PDE4 1 ± 10 0.01 (manufacturers) 0.1 mM NaOH 0.1 ± 10 mM Zardaverine PDE3/4 0.58 0.17 (Schudt et al., 1991a) 0.001% DMSO 0.1 ± 3 mM *Adenosine receptor antagonism; {Solvent of the highest drug concentration; {Concentration range of PDE inhibitors applied prior to the allergen challenges; only the respective highest concentrations of the PDE inhibitors were used for the LTC 4 challenges. potent than histamine in non-sensitized and 7500 fold more potent in passively sensitized tissues (Table 2) .
Maximal contractions of sensitized bronchial rings to allergen were on average 80% of the maximal responses to histamine ( Figure 1 , Table 2 ). Since concentrations of 3 nM LTC 4 and 10 u ml 71 D. farinae caused contractile responses of similar magnitude (approximately 75% of the maximal contraction to histamine; Figure 1 ), the eects of PDE inhibitors on allergen-and LTC 4 -induced contractile responses were evaluated and compared at these concentrations of spasmogens (Table 3) .
Effect of the PDE inhibitors on inherent tone
PDE inhibitors decreased resting tension in concentration dependent manner within the indicated concentration range ( Table 1 ). The highest concentrations of the non-selective PDE inhibitors theophylline and IBMX, as well as the selective PDE3 inhibitor motapizone, the PDE4 selective inhibitors RP73401, rolipram and AWD 12-281, the combination of motapizone and RP73401 and the PDE3/4 inhibitor zardaverine, signi®cantly relaxed bronchial rings compared to the respective solvent controls (P50.05, for each; Figure 2 ). In contrast, the adenosine receptor antagonist, 8-phenyltheophylline, had no signi®cant eect as compared to the solvent control. However, when relaxation was compared among all of these drugs by ANOVA, there was no signi®cant dierence in their relaxant eects.
Effect of the PDE inhibitors on allergen-induced contractions
The non-selective PDE inhibitors theophylline and IBMX inhibited the contractile responses to allergen in concentration dependent manner (Figure 3a,b) . The concentrationeect curves were shifted to the right with a concomitant reduction of the maximal allergen responses.
In contrast, even the highest concentrations of the methylxanthine adenosine receptor antagonist 8-phenyltheophylline (Figure 3c ), the PDE3-selective inhibitor motapizone (Figure 3d ) and the PDE4-selective inhibitors RP73401 (Figure 3e ) and rolipram ( Figure 3f ) had no signi®cant inhibitory eect on the contractile responses to allergen.
However, the novel PDE4-selective inhibitor AWD 12-281 inhibited allergen-induced bronchoconstriction in a concentration dependent manner ( Figure 3g) ; the highest concentration signi®cantly reduced allergen responses.
Allergen-induced bronchoconstriction was inhibited in a concentration dependent manner by combining motapizone and RP73401, selective PDE3 and PDE4 inhibitors, respectively (Figure 3h ), and by 3 mM of the combined PDE3/4 selective inhibitor zardaverine (Figure 3i) . The concentrationeect curves were shifted to the right with a reduction of the maximal responses, while the highest concentrations of motapizone+RP73401 completely abolished allergen-induced bronchoconstriction (Figure 3h) .
Effect of the PDE inhibitors on LTC 4 -induced contractions
Theophylline ( Table 3 summarizes and compares the described eects of the dierent agents on allergen-and LTC 4 -induced bronchoconstriction at submaximal concentrations of the spasmogens (10 u ml 71 allergen, 3 nM LTC 4 ) that caused similar contractions in control tissues, i.e. approx. 75% of the maximal response to histamine (see Figure 1) .
Effect of selective PDE inhibitors on allergen-precontracted bronchi
The combination of the PDE3-selective inhibitor motapizone (1 mM) and the PDE4-selective inhibitor RP73401 (300 nM) completely relaxed allergen-induced bronchial tone in passively sensitized airways pre-contracted with 30 u ml 71 D. farinae (n=5). The selective inhibition of PDE3 by motapizone reduced induced tone by 76+6%, inhibition of PDE4 by RP73401 reduced tone by 74+7% (n=4). In either case the remaining tone was completely relaxed by addition of the other inhibitor ( Figure 5 ).
Discussion
The present study demonstrates that combined inhibition of PDE3 and PDE4, but not selective inhibition of the individual isoenzymes, is eective in suppressing allergeninduced contractions of passively sensitized human airways. The combination of PDE3 and PDE4 inhibition was as eective as the non-selective inhibition by theophylline in suppressing allergen responses, while adenosine antagonism had no eect in preventing bronchoconstriction.
The in vitro model of passively sensitized human airways, i.e. the incubation of isolated airways with IgE-rich serum obtained from atopic individuals, closely mimics features of bronchial hyperresponsiveness as observed in patients with extrinsic bronchial asthma. On one hand, these features comprise non-speci®c hyperresponsiveness to stimuli, such as histamine and leukotrienes, that can be observed in subjects with asthma in vivo (O'Hickey et al., 1988) as well as in passively sensitized airways in vitro (Watson et al., 1997) , again con®rmed by the present study. On the other hand, isolated sensitized airways demonstrate speci®c hyperresponsiveness to allergen that is mediated through the release of in¯ammatory mediators, mainly cysteinyl leukotrienes, under in vivo (BjoÈ rck et al., 1991) as well as in vitro conditions (BjoÈ rck et al., 1991; BjoÈ rck & DahleÂ n, 1993; Roquet et al., 1997) .
In patients with asthma, early and late phase allergic responses can be inhibited by theophylline through mechanisms which might involve its ability to elicit bronchodilation (Pauwels et al., 1985) but also immunomodulatory and antiin¯ammatory activity (Banner & Page, 1996) . Since treatment with theophylline is associated with considerable side-eects, we aimed to investigate whether its bene®cial eects are dependent on the non-speci®c inhibition of PDEs and/or adenosine receptor antagonism ± both of which mechanisms are believed to be responsible for the unwanted eects ± or whether the bene®ts could be attributed to the inhibition of certain PDE isoenzymes.
Our data demonstrate that allergen-induced contraction of passively sensitized human airways in vitro was eectively suppressed only by the simultaneous inhibition of PDE3 and PDE4 through the use of the non-selective inhibitors theophylline and IBMX, the PDE3/4 selective inhibitor zardaverine or the combination of a selective PDE3 and PDE4 inhibitor (motapizone+RP73401). Remarkably, neither the inhibition of the individual PDE3 isoenzyme by motapizone nor of PDE4 by RP73401 or rolipram was sucient to alter allergen responses signi®cantly, nor did the mathematical addition of the individual eects of these isoenzyme inhibitors result in a signi®cant inhibitory eect on allergen responses.
Surprisingly ± and at ®rst sight in contrast to the PDE4-selective inhibitors rolipram and RP73401 ± the novel PDE4 inhibitor AWD 12-281 signi®cantly reduced the bronchospasmogenic eect of allergen. It is conceivable that this inhibition of allergen-induced bronchoconstriction by AWD 12-281 is caused by a dierent mode of action as compared to the other PDE4 inhibitors tested. However, the exact site of interaction with the PDE is not known so far and, therefore, this assumption could be only based on speculation. More likely AWD 12-281 exhibits bronchoprotective eects through a loss of its PDE4 selectivity at higher concentrations, thereby gaining additional activity against PDE3 (Table 1) . This latter possibility would be in line with our ®ndings that a simultaneous inhibition of PDE3 and PDE4 is necessary to signi®cantly decrease allergen responses in passively sensitized human airways.
Until a few years ago it was believed that PDE inhibitors aect airway function primarily through relaxation of airway smooth muscle resulting from cyclic AMP elevation and subsequent phosphorylation of muscle regulatory proteins and attenuation of cellular Ca 2+ concentrations. However, in our study all PDE inhibitors demonstrated comparable bronchorelaxant eects. Even selective inhibition of PDE3 (motapizone) or PDE4 (RP73401, rolipram), which had no eect on allergen-induced contractions, decreased resting tension of passively sensitized bronchial rings by a similar magnitude to theophylline. This lack of a correlation between the bronchorelaxant and bronchoprotective eects of the PDE inhibitors renders it unlikely that the observed protection against allergen-induced responses resulted exclusively from a prior decrease in bronchial tone through smooth muscle relaxation. Our ®ndings are in line with the clinical observation that, in patients with asthma, allergeninduced bronchoconstriction as well as bronchial responsiveness to methacholine and histamine are eectively reduced by theophylline, while baseline lung function is only weakly aected (Magnussen et al., 1986; 1987; Ward et al., 1993) . Taken together, these ®ndings reinforce the idea that bronchorelaxant and bronchoprotective eects of PDE inhibitors are not necessarily linked and might involve mechanisms other than direct eects on airway smooth muscle.
Furthermore, it has been suggested that methylxanthines such as theophylline and IBMX might exhibit their eects in part through adenosine receptor antagonism (Karlsson, 1987; Coward et al., 1998; Crimi et al., 1989) . However, in the present study the adenosine receptor antagonist, 8-phenyltheophylline, had no eect on bronchial tone or allergen responses in passively sensitized preparations. This ®nding suggests that adenosine receptor antagonism is unlikely to be an important mechanism through which methylxanthines relax bronchial tone and protect against allergen-induced bronchoconstriction in passively sensitized human airways.
On the other hand, inherent tone of isolated human airways is believed to result mainly from the spontaneous release of cysteinyl leukotrienes and histamine from resident in¯ammatory cells such as mast cells and also eosinophils in the airway wall (Peters et al., 1984; Schleimer et al., 1986; Hay et al., 1993; Ellis & Undem, 1994) . The combination of antagonists of CysLT and H 1 histamine receptors was as eective as isoprenaline in relaxing human airways in vitro (Ellis & Undem, 1994) . As pre-treatment with b-agonists does not modify concentration eect-curves of LTC 4 (Gorenne et al., 1995) , it could be assumed that cyclic AMP-elevating drugs such as PDE inhibitors and b-adrenoceptor agonists might exhibit their eects on basal bronchial tone at least in part through the inhibition of endogenous mediator release.
Independently of their bronchorelaxant capacity, PDE inhibitors are also believed to exhibit their eects on allergen-induced bronchoconstriction through inhibition of the formation and release of in¯ammatory mediators, mainly cysteinyl leukotrienes. If this were the case, PDE inhibitors that protect against allergen should be signi®cantly less eective against contractions induced by these mediators. Our study, however, showed that LTC 4 -induced bronchoconstriction was eectively reduced by the same PDE inhibitors ± or their combination ± that inhibited allergen responses (Table 3) . LTC 4 -and allergen-induced contractions were reduced to a similar degree by the simultaneous inhibition of PDE3 and PDE4 through the use of the nonselective inhibitors theophylline and IBMX, the PDE3/4 selective inhibitor zardaverine, AWD 12-281 or the combination of a selective PDE3 (motapizone) and PDE4 inhibitor (RP73401).
Furthermore, it is noteworthy that allergen-precontracted airways were signi®cantly relaxed by the individual inhibition of PDE3 or PDE4, while their combination caused a complete decrease in bronchial tone to the level prior to the addition of allergen. The completeness of the relaxation was dependent on the presence of both selective inhibitors but was not altered if one of them had been added already prior to the induction of contraction by allergen. These ®ndings suggest that PDE3 and PDE4 co-regulate cyclic AMP content in human airway smooth muscle. Other studies support this hypothesis, as either a combination of PDE3 and PDE4 inhibitors or dual PDE3/4 inhibitors produce a much greater bronchospasmolytic eect in carbachol-precontracted airway preparations than individual isoenzyme-selective agents alone (de Boer et al., 1992; Torphy et al., 1993) .
The relationship between the eects of PDE inhibitors on isolated airways under various conditions ± i.e. resting tension versus allergen and leukotriene responsiveness and allergeninduced tone ± suggests that dierent mechanisms might be involved. While the bronchoprotective and bronchospasmolytic eect of PDE inhibitors with selectivity for PDE3 and PDE4 (non-selective, PDE3-selective+PDE4-selective, PDE3/ 4-selective inhibitors) appear to result mainly from a direct eect on airway smooth muscle, their eect on resting tension is likely to be primarily mediated through the inhibition of mediator release from in¯ammatory cells within the airway wall. Experiments on human lung mast cells have shown that mast cells contain PDE3 and PDE4 (Tenor & Schudt, 1996; Weston et al., 1997) , and that both PDE3 and PDE4 inhibitors are eective in reducing antigen-driven mediator release from these cells (Louis et al., 1992; Anderson & Peachell, 1994) . This might form one explanation for the similar eects of all PDE inhibitors tested in this study, including the PDE3-selective inhibitor motapizone and the PDE4-selective inhibitors RP73401 and rolipram, on resting tension. Taken together, these ®ndings suggest that PDE inhibitors' mode of action comprises eects on smooth muscle as well as in¯ammatory cells and that the relative contributions of the two mechanisms might vary depending on the conditions. Whether these ®ndings hold true for the clinical use of selective PDE inhibitors remains to be shown. First clinical studies on the eect of the PDE3-selective inhibitor olprinone and the PDE4-selective inhibitor SB 207499, demonstrated very variable and mild eects on baseline lung function, Figure 4 Eect of the selective and non-selective PDE inhibitors on leukotriene (LT) C 4 -induced contraction in passively sensitized human airways. Compared to sensitized controls, LTC 4 -induced contractions were reduced by pre-treatment with the non-selective PDE inhibitors theophylline (a) and IBMX (b), the PDE4-selective inhibitor AWD 12-281 (g), the combination of a PDE3-(motapizone) and PDE4-selective (RP 73401) inhibitor (Mota+RP73401) (h), and the PDE3/4-selective inhibitor zardaverine (i). Pretreatment with the adenosine receptor antagonist 8-phenyltheophylline (c), the PDE3-selective inhibitor motapizone (d), the PDE4-selective inhibitors RP73401 (e) and rolipram (f) did not aect LTC 4 -induced contractions. Tension changes are expressed as per cent of the maximal responses to histamine in the same tissues. **P50.01 and ***P50.001, denote the comparison of whole concentration-eect curves by ANOVA. comparable with those eects observed after theophylline (Magnussen et al., 1986; Myou et al., 1999; Torphy et al., 1999) . Importantly, neither study with the selective PDE inhibitors ± the PDE3 inhibitor was inhaled, the PDE4 inhibitor was administered orally ± showed any signi®cant adverse eects of the drugs. On the basis of our ®ndings it could be assumed that selective PDE inhibitors, although demonstrating similar eects on baseline lung function, could aect bronchial obstruction and airway in¯ammation to a dierent degree. However, to evaluate the characteristic eects of PDE3-and PDE4-selective inhibitors, future clinical studies with these novel drugs and/or their combinations might have to focus on possible anti-in¯ammatory and bronchoprotective eects as study endpoints rather than looking exclusively at changes in baseline lung function parameters.
The present in vitro data suggest that phosphodiesterase inhibitors with a combined selectivity for PDE3 and PDE4 are likely to be eective drugs for the treatment of bronchial asthma, whereas the development of highly selective drugs might have no additional advantages and rather lack eectiveness. PDE inhibitors with combined selectivity for PDE3 and PDE4 appear to exert their eects on human airways in vitro by a dual mechanism involving direct relaxing eects on airway smooth muscle and inhibition of mediator formation and/or release from in¯ammatory cells. However, their relative importance and implication remain to be demonstrated in clinical studies that look not only on the eects on baseline lung function but also on in¯ammatory parameters and bronchial responsiveness. Those studies would show whether the selective phosphodiesterase inhibitors are eective in the treatment of obstructive airway diseases and on the other demonstrate an improved side eect pro®le in comparison with theophylline. ). The bronchospasmolytic eects of (a) motapizone followed by RP73401 and (b) RP73401 followed by motapizone were recorded. In either case a complete relaxation of the allergen-precontracted bronchial ring was achieved.
